Marinus Pharmaceuticals Inc logo

Marinus Pharmaceuticals Inc Share Price (NASDAQ: MRNS)

▲

-0.55

(-100%)

Last updated on

Bell Icon

The stock has been delisted from the stock exchange on 10 Feb 2025

Check the interactive Marinus Pharmaceuticals Inc Stock chart to analyse performance

Marinus Pharmaceuticals Inc Key Stats

Check Marinus Pharmaceuticals Inc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$0.5495
Open
$0.5492
Market Capitalization
$30.3M
Today's Volume
$1.1M
Revenue TTM
$30.3M
EBITDA
$-128.7M
Earnings Per Share (EPS)
$-2.47
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-2986.55%

Global Institutional Holdings in Marinus Pharmaceuticals Inc

  • Name

    Holdings %

  • Suvretta Capital Management, LLC

    9.19%

  • Franklin Resources Inc

    8.54%

  • TANG CAPITAL MANAGEMENT LLC

    8.51%

  • Sofinnova Ventures

    7.94%

  • Vanguard Group Inc

    5.08%

  • Bain Capital Life Sciences Investors, LLC

    4.88%

Analyst Recommendation on Marinus Pharmaceuticals Inc Stock

Rating
Trend

Buy

    76%Buy

    23%Hold

    0%Sell

Based on 17 Wall street analysts offering stock ratings for Marinus Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)

About Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Organization
Marinus Pharmaceuticals Inc
Employees
165
CEO
Dr. Scott N. Braunstein M.D.
Industry
Health Technology

Key Management of Marinus Pharmaceuticals Inc

NameTitle
Dr. Scott N. Braunstein M.D.
CEO, President & Chairman
Mr. Steven E. Pfanstiel C.M.A., M.B.A.
COO, CFO & Treasurer
Dr. Joseph Hulihan M.D.
Chief Medical Officer
Dr. Alex Aimetti Ph.D.
Chief Scientific Officer
Ms. Sonya Weigle
Senior VP of Investor Relations, Human Resources & Corporate Affairs
Ms. Martha E. Manning Esq., J. D.
Senior VP, General Counsel & Secretary
Molly Cameron
Director of Corporate Communications & Investor Relations
Dr. Kimberly A. McCormick Pharm.D.
Chief Regulatory & Quality Assurance Officer
Ms. Christina Shafer
Chief Commercial Officer
Mr. David Czekai
Chief Chemistry, Manufacturing & Controls Officer

Important FAQs about investing in MRNS Stock from India :

What is Marinus Pharmaceuticals Inc share price today?

Marinus Pharmaceuticals Inc share price today is as on at the close of the market. Marinus Pharmaceuticals Inc share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Marinus Pharmaceuticals Inc share?

Marinus Pharmaceuticals Inc share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Marinus Pharmaceuticals Inc stock price today i.e. is closed at , lower by 100% versus the 52 week high.

How to invest in Marinus Pharmaceuticals Inc Stock (MRNS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Marinus Pharmaceuticals Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Marinus Pharmaceuticals Inc Shares .

What is the minimum amount required to buy Marinus Pharmaceuticals Inc Stock (MRNS) from India?

Indian investors can start investing in Marinus Pharmaceuticals Inc (MRNS) shares with as little as ₹88.059 or $1 (as of October 16, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹880.59 in Marinus Pharmaceuticals Inc stock (as per the Rupee-Dollar exchange rate as on October 16, 2025). Learn more about fractional shares .

What are the returns that Marinus Pharmaceuticals Inc has given to Indian investors in the last 5 years?

Marinus Pharmaceuticals Inc stock has given 0.0% share price returns and 19.91% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?